Tevogen CEO addresses broader implications of short-selling

Tevogen Bio (TVGN) issued a statement from its Founder and CEO Ryan Saadi regarding broader implications of short-selling. “Tevogen Bio is committed to advancing innovative medical solutions while maintaining affordability for patients, a mission that is essential for sustainable healthcare innovation. Since going public, we have made significant progress, including a collaboration between Tevogen.AI and Microsoft (MSFT) to explore AI applications in biotechnology. Despite these advancements, our share price has faced pressure,” said Saadi. “This brings into question the indirect impact of short-selling on healthcare innovation, where executives of emerging biopharma companies might divert attention to defending against short attacks rather than focusing on critical priorities like patient accessibility, national security initiatives, and supporting President Trump and Secretary Kennedy’s efforts to strengthen our healthcare system.”